Seeking Alpha

CytRx reports further evidence in support of aldoxorubicin

  • CytRx (CYTR) is out with more data in support of aldoxorubicin efficacy.
  • The "additional statistical analyses" of the Phase 2b study determined the hazard ratios on the PFS endpoint: HR for investigator-read scans, 0.37; HR for central lab scans, 0.59.
  • The company also says a Kaplan-Meier analysis "showed significant improvement in subjects treated with aldoxorubicin versus subjects treated with doxorubicin." (PR)
  • For the originally reported results, see here.
  • CYTR +10% premarket
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs